Personalized Chinese medicine for post-surgery colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding personalized Traditional Chinese Medicine to standard chemotherapy helps people with stage III colorectal cancer recover better after surgery. It's for patients who need chemotherapy and are open to trying TCM.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old.
- Have stage III colorectal cancer that needs chemotherapy after surgery.
- Be willing to take Traditional Chinese Medicine.
- Have good kidney and liver function (based on blood tests).
- Not have had any prior cancer treatment (chemotherapy, radiation, or immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This Phase 3 study tests whether a Chinese herbal “decoction” (called XLJDOD) given after surgery and chemo can lower the chance that colon cancer comes back. It may help people with higher-risk colon cancer (Stage IIIB or IIIC) stay cancer-free longer.
This trial tests putting a chemo drug (fluorouracil) directly into the colon through a tube. It's for people with colorectal cancer who are already getting other cancer treatment, to see if adding local chemo helps shrink the main tumor.
This study looks at whether staged Chinese herbal medicine added to standard treatment can lower the risk of lung cancer coming back or spreading after surgery. It is for people with stage Ib to IIIb non-small cell lung cancer whose tests show no “driver gene” targets.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
Hear when a new Locally Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.